Laborie Medical Technologies has announced plans to acquire the JADA System from Organon in a deal valued at up to $465 million. The agreement includes an upfront payment of $440 million upon closing, with an additional $25 million tied to achieving 2026 revenue milestones.
The JADA System, which has been cleared by the U.S. Food and Drug Administration (FDA), is designed for the rapid treatment and control of abnormal postpartum uterine bleeding or haemorrhage when conservative management is appropriate. It is currently available in over 20 countries and used in more than 2,000 hospitals across the United States.
The transaction, pending regulatory approval and other closing conditions, is expected to be finalised in the first quarter of 2026.
“Childbirth is one of the most personal and profound moments in a woman’s life, and every mother deserves to feel supported throughout it,” said Chris Smith, President and CEO of Laborie. “The JADA System helps care teams provide treatment when it matters most and being part of that mission is something we hold with deep pride and purpose at Laborie.”
According to Organon, the JADA System has already been used to assist more than 136,000 mothers globally.
“This transaction puts a med tech asset in the hands of Laborie, a leading medical technology innovator with an established history in maternal health well-positioned to further expand access to JADA for the benefit of mothers globally,” said Joseph Morrissey, interim Chief Executive Officer at Organon.
Laborie, based in Portsmouth, New Hampshire, specialises in urology, urogynecology, gastroenterology, obstetrics, gynecology, and neonatal health. The company is part of Patricia Industries, a division of Investor AB.
